Another recent study demonstrates that intranasal vaccination with a commercial influenza vaccine adjuvanted with NexaVant (NVT), a TLR3 agonist, effectively boosts lung CD4+ TRM cells, which are key to cross-protective, long-lasting immunity against diverse influenza strains. This evidence concerns the gene TLR3 and influenza.